Abstract:Purpose/Objective(s) Achieving optimal tumor dose while minimizing organ at risk (OAR) uptake is a critical challenge for targeted radionuclide therapy (TRT), due to highly variable tumor uptake and biodistribution from patient to patient. Moreover, TRT is delivered using a standard dosing regimen for all patients, without knowledge if an ablative tumor dose, or critical OAR dose, has been reached. This potentially compromises outcomes that could be addressed by modulating the administered dose. SPECT-based dosimetry provides a snap-shot of body-wide dose distribution, but it is generally limited in availability and to a single time point. Therefore, methods for obtaining the total integrated dose for all patients are critically needed. A highly sensitive in vivo microdosimeter (IVµD) implanted within the tumor and OAR via biopsy needle solves this problem by monitoring the dose within the body in real time. Here, we demonstrate the world's first sub-mm3 single charged particle sensitive IVµD and its applicability to Lu177-based TRT. The low power consumption (<0.6 mW) and miniaturized form factor (0.27 mm3) are compatible with in vivo implantation for continuous monitoring of TRT delivery and personalized dosing. Materials/Methods To achieve single particle detection, an array of ultra-small (1 µm2) diodes are integrated with in-pixel amplifiers on a 0.9 mm2 integrated circuit. For each emitted beta-particle that intersects the chip, ∼1/3 of the deposited energy in the diode's depletion region creates electron-hole pairs. The generated electrons are then integrated on the diode's parasitic capacitor (Cp). Because the amplitude of the voltage signal, Vp, is inversely proportional to Cp, a nearly minimum size diode (1 µm2, with Cp = 2.4 fF) maximizes Vp from the single hit. The diodes are arranged in a 64 ⨉ 64 array, providing a total detection area of 512 ⨉ 512 µm2 in a monolithic silicon chip-let. Lu177 is diluted to 10 different concentrations ranging from 1.5 ⨉ 10−3∼1.2 µCi/µL, equivalent to 0.18∼146 %ID/g assuming 800 µCi of injection, matching and exceeding the therapeutic dose range of 0.97∼649 Gy. The device is submerged in the tube and measures the activity of each solution for more than 40 minutes. Results The measured counts per minute (CPM) is highly proportional to the concentration over a wide range without saturation. The least square linear regression relationship between the measured CPM and concentration is CPM = 1290 ⨉ concentration (in µCi/µL), and highly linear with an R2 value of 0.9998. The measured mean and the standard error of CPM ranges from 1.9 ± 0.8 CPM (at 1.5 ⨉ 10−3 µCi/µL, or 0.18 %ID/g) to 1510 ± 46 CPM (at 1.2 µCi/µL, or 146 %ID/g), demonstrating the wide dynamic range necessary to measure low uptake organs at risk and high uptake tumors. Conclusion A sub-mm3 diode based IVµD capable of detecting single beta-particles in real-time was demonstrated using solutions of Lu177. We envision that such a device can be used to optimize TRT dosing on a per-patient level improving clinical outcomes.

A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells In Vitro

Quantifying Imaging Agent Binding and Dissociation in 3-D Cancer Spheroid Tissue Culture Using Paired-Agent Principles

Low cost, high temporal resolution optical fiber-based γ-photon sensor for real-time pre-clinical evaluation of cancer-targeting radiopharmaceuticals

Radioligand Saturation Binding for Quantitative Analysis of Ligand-Receptor Interactions

Label-Free Quantification of Molecular Interaction in Live Red Blood Cells by Tracking Nanometer Scale Membrane Fluctuations.

In Situ Drug-Receptor Binding Kinetics in Single Cells: a Quantitative Label-Free Study of Anti-Tumor Drug Resistance

SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy

Personalized Lu177 Theranostic Dosimetry Using a Single Beta-Particle In Vivo Microdosimeter

Molecular Biotheranostic Approaches of Cancers Using LAT Kit Probes

Ex Vivo Radiolabeling and In Vivo PET Imaging of T Cells Expressing Nuclear Reporter Genes

Non-invasive kinetic modelling of PET tracers with radiometabolites using a constrained simultaneous estimation method: evaluation with 11C-SB201745

Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors

A technique to quantify very low activities in regions of interest with a collimatorless detector

ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations for 223Ra-Based Radiopharmaceutical Therapies

A Novel Pretargeting Method for Measuring Antibody Internalization in Tumor Cells

A Novel Method Measuring Internalization in Tumor Cells by Cell Pretargeting

A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal model

A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates

Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging

Quantitative radio-thin-layer chromatography and positron emission tomography studies for measuring streptavidin transduced chimeric antigen receptor T cells

99Mtc-Labeled Mutant Interleukin-2 As a Promising SPECT Probe for in Vivo Imaging of Tumor-Infiltrating T Cells